HUE049591T2 - Macrocyclic mcl1 inhibitors for treating cancer - Google Patents
Macrocyclic mcl1 inhibitors for treating cancerInfo
- Publication number
- HUE049591T2 HUE049591T2 HUE17720720A HUE17720720A HUE049591T2 HU E049591 T2 HUE049591 T2 HU E049591T2 HU E17720720 A HUE17720720 A HU E17720720A HU E17720720 A HUE17720720 A HU E17720720A HU E049591 T2 HUE049591 T2 HU E049591T2
- Authority
- HU
- Hungary
- Prior art keywords
- macrocyclic
- treating cancer
- mcl1 inhibitors
- mcl1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049591T2 true HUE049591T2 (en) | 2020-09-28 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17720720A HUE049591T2 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (en) |
| EP (1) | EP3445767B1 (en) |
| JP (1) | JP6894449B2 (en) |
| KR (1) | KR102388208B1 (en) |
| CN (1) | CN109071566B (en) |
| AR (1) | AR108301A1 (en) |
| AU (1) | AU2017252222B2 (en) |
| BR (1) | BR112018070677B1 (en) |
| CA (1) | CA3020378A1 (en) |
| CL (1) | CL2018002410A1 (en) |
| CO (1) | CO2018008759A2 (en) |
| CR (1) | CR20180499A (en) |
| CY (1) | CY1123186T1 (en) |
| DK (1) | DK3445767T3 (en) |
| DO (1) | DOP2018000222A (en) |
| EA (1) | EA036551B1 (en) |
| ES (1) | ES2791319T3 (en) |
| HR (1) | HRP20200673T1 (en) |
| HU (1) | HUE049591T2 (en) |
| IL (1) | IL262237B (en) |
| LT (1) | LT3445767T (en) |
| MA (1) | MA44721B1 (en) |
| ME (1) | ME03729B (en) |
| MX (1) | MX2018012711A (en) |
| NI (1) | NI201800093A (en) |
| PE (1) | PE20181803A1 (en) |
| PH (1) | PH12018502227A1 (en) |
| PL (1) | PL3445767T3 (en) |
| PT (1) | PT3445767T (en) |
| RS (1) | RS60257B1 (en) |
| SG (1) | SG11201805838UA (en) |
| SI (1) | SI3445767T1 (en) |
| SV (1) | SV2018005742A (en) |
| TN (1) | TN2018000319A1 (en) |
| TW (1) | TWI742074B (en) |
| WO (1) | WO2017182625A1 (en) |
| ZA (1) | ZA201807766B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697729B (en) | 2016-02-04 | 2023-05-09 | 约翰霍普金斯大学 | Novel GLUT inhibitor rapaglutin and application thereof |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| EP3411032B1 (en) | 2016-02-04 | 2020-09-30 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| SG11201805838UA (en) | 2016-04-22 | 2018-11-29 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
| CN109715632B (en) | 2016-05-19 | 2021-10-26 | 拜尔公开股份有限公司 | Macrocyclic indole derivatives |
| TWI781996B (en) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | Methods of synthesizing an mcl-1 inhibitor |
| TW201904976A (en) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Mcl-1 inhibitors and methods of use thereof |
| CA3073112A1 (en) | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| BR112020003163A2 (en) * | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | macrocyclic mcl-1 inhibitors and methods of use |
| UY37973A (en) | 2017-11-17 | 2019-06-28 | Bayer Ag | MACROCYCLIC INDOL DERIVATIVES |
| UY37972A (en) * | 2017-11-17 | 2019-06-28 | Bayer Pharma AG | MACROCYCLIC INDOL DERIVATIVES SUBSTITUTED WITH CHLORINE |
| US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| CN111757884B (en) * | 2017-11-17 | 2023-12-19 | 拜耳股份公司 | Substituted macrocyclic indole derivatives |
| US11447504B2 (en) | 2017-11-17 | 2022-09-20 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| EP3710449B1 (en) * | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| TW202014184A (en) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | Combinations for treating cancer |
| WO2020063792A1 (en) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Indole macrocyclic derivative, preparation method therefor and application thereof in medicine |
| TWI810397B (en) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | Methods of treating cancer |
| CN111205309B (en) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Indole macrocyclic derivatives, preparation method and medical application thereof |
| WO2020103864A1 (en) * | 2018-11-22 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as mcl-1 inhibitors |
| EP3781575A4 (en) * | 2019-01-23 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| MX2021010321A (en) * | 2019-03-08 | 2021-11-17 | Zeno Man Inc | Macrocyclic compounds. |
| TW202106693A (en) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | A indole macrocyclic derivative, a preparation method thereof, and medical use thereof |
| JOP20210289A1 (en) | 2019-05-20 | 2023-01-30 | Servier Lab | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| MA56505A (en) * | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | MACROCYCLIC MCL-1 INHIBITORS |
| CA3144558A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| CA3157731A1 (en) | 2019-11-21 | 2021-05-27 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as mcl-1 inhibitors |
| JP2023502692A (en) | 2019-11-21 | 2023-01-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Macrocyclic Sulfonyl Derivatives as MCL-1 Inhibitors |
| JP2023510135A (en) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | macrocyclic compound |
| CN115151551A (en) | 2020-02-21 | 2022-10-04 | 詹森药业有限公司 | Macrocyclic indole derivatives as MCL-1 inhibitors |
| WO2021197295A1 (en) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | Crystalline form of macrocyclic indole derivative and preparation method therefor |
| CA3178283A1 (en) | 2020-05-29 | 2021-12-02 | Frederik Jan Rita Rombouts | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| KR20230026357A (en) | 2020-06-19 | 2023-02-24 | 얀센 파마슈티카 엔.브이. | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| US20230234965A1 (en) | 2020-06-19 | 2023-07-27 | Janssen Pharmaceutica Nv | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| AU2021306644A1 (en) | 2020-07-08 | 2023-03-09 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of MLC-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| IL303079A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| KR20230121807A (en) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of MCL-1 |
| AU2022220818A1 (en) | 2021-02-12 | 2023-09-28 | Janssen Pharmaceutica Nv | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| CN115490708A (en) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | Sulfonamide macrocyclic derivatives, and preparation method and application thereof |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| AR129380A1 (en) | 2022-05-20 | 2024-08-21 | Novartis Ag | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USING THE SAME |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445679B2 (en) * | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| ES2550753T3 (en) | 2007-04-16 | 2015-11-12 | Abbvie Inc. | Indole derivatives unsubstituted at position 7 as Mcl-1 inhibitors |
| MX2011006803A (en) * | 2008-12-22 | 2011-09-06 | Cubist Pharm Inc | Novel antibacterial agents for the treatment of gram positive infections. |
| WO2011079007A1 (en) * | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| KR101953210B1 (en) * | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | Macrocyclic Compounds as Protein Kinase Inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| US10005728B2 (en) | 2013-08-28 | 2018-06-26 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| ES2654242T3 (en) * | 2014-02-12 | 2018-02-12 | Viiv Healthcare (No.5) Limited | Benzotiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| CA2943815C (en) | 2014-03-27 | 2023-04-04 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| AU2015243585B2 (en) * | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| SG11201805838UA (en) | 2016-04-22 | 2018-11-29 | Astrazeneca Ab | Macrocyclic mcl1 inhibitors for treating cancer |
-
2017
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/en unknown
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/en unknown
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/en active Active
- 2017-04-21 MA MA44721A patent/MA44721B1/en unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/en unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/en unknown
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/en unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/en active Active
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/en active Active
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/en active IP Right Grant
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 EA EA201892300A patent/EA036551B1/en not_active IP Right Cessation
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/en unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/en active IP Right Grant
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 RS RS20200549A patent/RS60257B1/en unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/en active
- 2017-04-21 TW TW106113380A patent/TWI742074B/en active
- 2017-04-21 CR CR20180499A patent/CR20180499A/en unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/en unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/en unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/en unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/en unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/en unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/en unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/en unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/en unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/en unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/en unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807766B (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| HK1251407A1 (en) | Methods for treating cancer | |
| ZA201706616B (en) | Method for treating cancer | |
| IL304252A (en) | Method for treating cancer | |
| IL289947A (en) | Method for treating cancer | |
| HK1249469A1 (en) | Methods for treating cancer with rorgamma inhibitors | |
| IL257691A (en) | Method for treating cancer | |
| HK1250944A1 (en) | Methods for treating cancer | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| HK1250942A1 (en) | Methods for treating cancer | |
| HK1250943A1 (en) | Methods for treating cancer | |
| SG10201508795XA (en) | Method for treating cancer | |
| IL265537A (en) | Methods for treating ovarian cancer |